Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
BackgroundImmune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous...
Saved in:
| Published in: | Journal for immunotherapy of cancer Vol. 9; no. 1; p. e001731 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BMJ Publishing Group LTD
01-01-2021
BMJ Publishing Group |
| Series: | Original research |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | BackgroundImmune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.MethodsPatients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. ICI-pneumonitis was defined as clinical or radiographic lung inflammation without an alternative diagnosis, confirmed by a multidisciplinary team. Steroid-refractory ICI-pneumonitis was defined as lack of clinical improvement after high-dose corticosteroids for 48 hours, necessitating additional immunosuppression. Serial clinical, radiologic (CT imaging), and functional features (level-of-care, oxygen requirement) were collected preadditional and postadditional immunosuppression.ResultsOf 65 patients with ICI-pneumonitis, 18.5% (12/65) had steroid-refractory ICI-pneumonitis. Mean age at diagnosis of ICI-pneumonitis was 66.8 years (range: 35–85), 50% patients were male, and the majority had lung carcinoma (75%). Steroid-refractory ICI-pneumonitis occurred after a mean of 5 ICI doses from PD-(L)1 start (range: 3–12 doses). The most common radiologic pattern was diffuse alveolar damage (DAD: 50%, 6/12). After corticosteroid failure, patients were treated with: IVIG (n=7), infliximab (n=2), or combination IVIG and infliximab (n=3); 11/12 (91.7%) required ICU-level care and 8/12 (75%) died of steroid-refractory ICI-pneumonitis or infectious complications (IVIG alone=3/7, 42.9%; infliximab alone=2/2, 100%; IVIG + infliximab=3/3, 100%). All five patients treated with infliximab (5/5; 100%) died from steroid-refractory ICI-pneumonitis or infectious complications. Mechanical ventilation was required in 53% of patients treated with infliximab alone, 80% of those treated with IVIG + infliximab, and 25.5% of those treated with IVIG alone.ConclusionsSteroid-refractory ICI-pneumonitis constituted 18.5% of referrals for multidisciplinary irAE care. Steroid-refractory ICI-pnuemonitis occurred early in patients’ treatment courses, and most commonly exhibited a DAD radiographic pattern. Patients treated with IVIG alone demonstrated an improvement in both level-of-care and oxygenation requirements and had fewer fatalities (43%) from steroid-refractory ICI-pneumonitis when compared to treatment with infliximab (100% mortality). |
|---|---|
| AbstractList | Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.
Patients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. ICI-pneumonitis was defined as clinical or radiographic lung inflammation without an alternative diagnosis, confirmed by a multidisciplinary team. Steroid-refractory ICI-pneumonitis was defined as lack of clinical improvement after high-dose corticosteroids for 48 hours, necessitating additional immunosuppression. Serial clinical, radiologic (CT imaging), and functional features (level-of-care, oxygen requirement) were collected preadditional and postadditional immunosuppression.
Of 65 patients with ICI-pneumonitis, 18.5% (12/65) had steroid-refractory ICI-pneumonitis. Mean age at diagnosis of ICI-pneumonitis was 66.8 years (range: 35-85), 50% patients were male, and the majority had lung carcinoma (75%). Steroid-refractory ICI-pneumonitis occurred after a mean of 5 ICI doses from PD-(L)1 start (range: 3-12 doses). The most common radiologic pattern was diffuse alveolar damage (DAD: 50%, 6/12). After corticosteroid failure, patients were treated with: IVIG (n=7), infliximab (n=2), or combination IVIG and infliximab (n=3); 11/12 (91.7%) required ICU-level care and 8/12 (75%) died of steroid-refractory ICI-pneumonitis or infectious complications (IVIG alone=3/7, 42.9%; infliximab alone=2/2, 100%; IVIG + infliximab=3/3, 100%). All five patients treated with infliximab (5/5; 100%) died from steroid-refractory ICI-pneumonitis or infectious complications. Mechanical ventilation was required in 53% of patients treated with infliximab alone, 80% of those treated with IVIG + infliximab, and 25.5% of those treated with IVIG alone.
Steroid-refractory ICI-pneumonitis constituted 18.5% of referrals for multidisciplinary irAE care. Steroid-refractory ICI-pnuemonitis occurred early in patients' treatment courses, and most commonly exhibited a DAD radiographic pattern. Patients treated with IVIG alone demonstrated an improvement in both level-of-care and oxygenation requirements and had fewer fatalities (43%) from steroid-refractory ICI-pneumonitis when compared to treatment with infliximab (100% mortality). BackgroundImmune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.MethodsPatients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. ICI-pneumonitis was defined as clinical or radiographic lung inflammation without an alternative diagnosis, confirmed by a multidisciplinary team. Steroid-refractory ICI-pneumonitis was defined as lack of clinical improvement after high-dose corticosteroids for 48 hours, necessitating additional immunosuppression. Serial clinical, radiologic (CT imaging), and functional features (level-of-care, oxygen requirement) were collected preadditional and postadditional immunosuppression.ResultsOf 65 patients with ICI-pneumonitis, 18.5% (12/65) had steroid-refractory ICI-pneumonitis. Mean age at diagnosis of ICI-pneumonitis was 66.8 years (range: 35–85), 50% patients were male, and the majority had lung carcinoma (75%). Steroid-refractory ICI-pneumonitis occurred after a mean of 5 ICI doses from PD-(L)1 start (range: 3–12 doses). The most common radiologic pattern was diffuse alveolar damage (DAD: 50%, 6/12). After corticosteroid failure, patients were treated with: IVIG (n=7), infliximab (n=2), or combination IVIG and infliximab (n=3); 11/12 (91.7%) required ICU-level care and 8/12 (75%) died of steroid-refractory ICI-pneumonitis or infectious complications (IVIG alone=3/7, 42.9%; infliximab alone=2/2, 100%; IVIG + infliximab=3/3, 100%). All five patients treated with infliximab (5/5; 100%) died from steroid-refractory ICI-pneumonitis or infectious complications. Mechanical ventilation was required in 53% of patients treated with infliximab alone, 80% of those treated with IVIG + infliximab, and 25.5% of those treated with IVIG alone.ConclusionsSteroid-refractory ICI-pneumonitis constituted 18.5% of referrals for multidisciplinary irAE care. Steroid-refractory ICI-pnuemonitis occurred early in patients’ treatment courses, and most commonly exhibited a DAD radiographic pattern. Patients treated with IVIG alone demonstrated an improvement in both level-of-care and oxygenation requirements and had fewer fatalities (43%) from steroid-refractory ICI-pneumonitis when compared to treatment with infliximab (100% mortality). Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.Methods Patients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. ICI-pneumonitis was defined as clinical or radiographic lung inflammation without an alternative diagnosis, confirmed by a multidisciplinary team. Steroid-refractory ICI-pneumonitis was defined as lack of clinical improvement after high-dose corticosteroids for 48 hours, necessitating additional immunosuppression. Serial clinical, radiologic (CT imaging), and functional features (level-of-care, oxygen requirement) were collected preadditional and postadditional immunosuppression.Results Of 65 patients with ICI-pneumonitis, 18.5% (12/65) had steroid-refractory ICI-pneumonitis. Mean age at diagnosis of ICI-pneumonitis was 66.8 years (range: 35–85), 50% patients were male, and the majority had lung carcinoma (75%). Steroid-refractory ICI-pneumonitis occurred after a mean of 5 ICI doses from PD-(L)1 start (range: 3–12 doses). The most common radiologic pattern was diffuse alveolar damage (DAD: 50%, 6/12). After corticosteroid failure, patients were treated with: IVIG (n=7), infliximab (n=2), or combination IVIG and infliximab (n=3); 11/12 (91.7%) required ICU-level care and 8/12 (75%) died of steroid-refractory ICI-pneumonitis or infectious complications (IVIG alone=3/7, 42.9%; infliximab alone=2/2, 100%; IVIG + infliximab=3/3, 100%). All five patients treated with infliximab (5/5; 100%) died from steroid-refractory ICI-pneumonitis or infectious complications. Mechanical ventilation was required in 53% of patients treated with infliximab alone, 80% of those treated with IVIG + infliximab, and 25.5% of those treated with IVIG alone.Conclusions Steroid-refractory ICI-pneumonitis constituted 18.5% of referrals for multidisciplinary irAE care. Steroid-refractory ICI-pnuemonitis occurred early in patients’ treatment courses, and most commonly exhibited a DAD radiographic pattern. Patients treated with IVIG alone demonstrated an improvement in both level-of-care and oxygenation requirements and had fewer fatalities (43%) from steroid-refractory ICI-pneumonitis when compared to treatment with infliximab (100% mortality). |
| Author | Feliciano, Josephine Marrone, Kristen Forde, Patrick M Lin, Cheng Ting Hann, Christine Zheng, Lei Balaji, Aanika Hsu, Melinda Danoff, Sonye K Lee, Valerie Suresh, Karthik Illei, Peter B Naidoo, Jarushka Brahmer, Julie R |
| AuthorAffiliation | 2 The Bloomberg~Kimmel Institute for Cancer Immunotherapy , Johns Hopkins University , Baltimore , Maryland , USA 4 Division of Pathology , Johns Hopkins University , Baltimore , MD , USA 5 Pulmonology and Critical Care Medicine , Johns Hopkins Medicine School of Medicine , Baltimore , Maryland , USA 3 Radiology , Johns Hopkins University , Baltimore , Maryland , USA 1 Oncology , Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center , Baltimore , Maryland , USA |
| AuthorAffiliation_xml | – name: 2 The Bloomberg~Kimmel Institute for Cancer Immunotherapy , Johns Hopkins University , Baltimore , Maryland , USA – name: 5 Pulmonology and Critical Care Medicine , Johns Hopkins Medicine School of Medicine , Baltimore , Maryland , USA – name: 1 Oncology , Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center , Baltimore , Maryland , USA – name: 3 Radiology , Johns Hopkins University , Baltimore , Maryland , USA – name: 4 Division of Pathology , Johns Hopkins University , Baltimore , MD , USA |
| Author_xml | – sequence: 1 givenname: Aanika orcidid: 0000-0001-6697-3364 surname: Balaji fullname: Balaji, Aanika email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 2 givenname: Melinda surname: Hsu fullname: Hsu, Melinda email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 3 givenname: Cheng Ting orcidid: 0000-0003-0275-8037 surname: Lin fullname: Lin, Cheng Ting email: jnaidoo1@jhmi.edu organization: Radiology, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 4 givenname: Josephine surname: Feliciano fullname: Feliciano, Josephine email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 5 givenname: Kristen surname: Marrone fullname: Marrone, Kristen email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 6 givenname: Julie R surname: Brahmer fullname: Brahmer, Julie R email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 7 givenname: Patrick M surname: Forde fullname: Forde, Patrick M email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 8 givenname: Christine surname: Hann fullname: Hann, Christine email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 9 givenname: Lei orcidid: 0000-0003-4163-2541 surname: Zheng fullname: Zheng, Lei email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 10 givenname: Valerie surname: Lee fullname: Lee, Valerie email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA – sequence: 11 givenname: Peter B surname: Illei fullname: Illei, Peter B email: jnaidoo1@jhmi.edu organization: Division of Pathology, Johns Hopkins University, Baltimore, MD, USA – sequence: 12 givenname: Sonye K surname: Danoff fullname: Danoff, Sonye K email: jnaidoo1@jhmi.edu organization: Pulmonology and Critical Care Medicine, Johns Hopkins Medicine School of Medicine, Baltimore, Maryland, USA – sequence: 13 givenname: Karthik surname: Suresh fullname: Suresh, Karthik email: jnaidoo1@jhmi.edu organization: Pulmonology and Critical Care Medicine, Johns Hopkins Medicine School of Medicine, Baltimore, Maryland, USA – sequence: 14 givenname: Jarushka orcidid: 0000-0002-3470-8686 surname: Naidoo fullname: Naidoo, Jarushka email: jnaidoo1@jhmi.edu organization: The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33414264$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkd1r1jAUxoNM3Jy790oK3ii-1aRJ08YLQebX4AUF9VJCkp7MlDZ5TVJh_72pnWO78iqHnOf8zsfzEB354AGhxwS_JITyV6PLpm5wg2uMSUfJPXTS4JbUhDX86FZ8jM5SGnERYUr7vn-Ajilla4adoB9fM8TghjqCjcrkEK-qL-_qZ_vnpDp4WObgXXbpdeW8cQN4A7vKTM47o6bKgspLhLSrcizhDD7vKuWHKizZhBnSI3TfqinB2fV7ir5_eP_t_FO9__zx4vztvtZtw3MNmgAI1VoQljPRKW0xteuI2nDVK8yJwLQ1hFOlObVCd7w3g9UtHxSnmJ6ii407BDXKQ3SzilcyKCf_foR4KVXMzkwg-44xLbhWQjFmrRWDgHIZbphgQrSqsN5srMOiZxhMWSqq6Q70bsa7n_Iy_JZdJ7qmW4d5eg2I4dcCKcsxLNGX_WXTto3oeY9FUeFNZWJIqVz_pgPBcvVXrv7K1V-5-VtKntye7Kbgn5tF8GIT6Hn8P-4Pziew5A |
| CitedBy_id | crossref_primary_10_1007_s15015_021_3382_x crossref_primary_10_1111_1759_7714_14693 crossref_primary_10_3892_ijo_2023_5570 crossref_primary_10_1097_CCO_0000000000000909 crossref_primary_10_1016_j_resmer_2022_100969 crossref_primary_10_1136_jitc_2023_006982 crossref_primary_10_3892_ol_2023_13874 crossref_primary_10_1177_11795549231210475 crossref_primary_10_1016_j_ando_2023_03_024 crossref_primary_10_3389_fimmu_2023_1082980 crossref_primary_10_1007_s13665_023_00314_z crossref_primary_10_1200_JCO_21_01440 crossref_primary_10_1093_oncolo_oyae147 crossref_primary_10_1016_j_lungcan_2023_107278 crossref_primary_10_1080_17476348_2024_2329612 crossref_primary_10_3390_cancers14102460 crossref_primary_10_1007_s00262_023_03528_x crossref_primary_10_3390_cancers16101892 crossref_primary_10_1002_rcr2_1356 crossref_primary_10_1186_s13613_023_01122_z crossref_primary_10_2147_OTT_S321965 crossref_primary_10_1002_rcr2_1115 crossref_primary_10_1007_s40278_021_92475_4 crossref_primary_10_1136_jitc_2023_007409 crossref_primary_10_1172_JCI170503 crossref_primary_10_1002_onco_13900 crossref_primary_10_1136_jitc_2020_002252 crossref_primary_10_1136_jitc_2022_006398 crossref_primary_10_1158_1078_0432_CCR_21_1240 crossref_primary_10_1038_s41467_022_27960_2 crossref_primary_10_3389_fimmu_2022_994064 crossref_primary_10_3389_fonc_2022_911906 crossref_primary_10_12688_f1000research_124457_1 crossref_primary_10_1016_j_ejca_2024_114065 crossref_primary_10_1136_jitc_2023_008591 crossref_primary_10_1016_j_pccm_2023_08_002 crossref_primary_10_2217_imt_2022_0028 crossref_primary_10_56305_001c_39747 crossref_primary_10_1001_jamaoncol_2021_3595 crossref_primary_10_1038_s41598_023_30676_y crossref_primary_10_7759_cureus_22295 crossref_primary_10_1007_s40264_023_01328_x crossref_primary_10_3389_fimmu_2024_1266850 |
| Cites_doi | 10.1136/bcr-2018-225937 10.1186/s40425-017-0210-0 10.1056/NEJMc1505197 10.1056/NEJMoa2004500 10.1148/radiology.211.1.r99ap10155 10.1007/s42399-020-00259-3 10.1200/JCO.2017.77.6385 10.1186/2051-1426-2-19 10.1200/JCO.2020.38.15_suppl.3078 10.6004/jnccn.2020.0012 10.1016/S1470-2045(18)30828-3 10.1186/s40425-017-0300-z 10.1148/rg.337130057 10.6004/jnccn.2018.7268 10.1016/j.rmcr.2019.100834 10.1016/j.ccm.2016.12.004 10.1177/1060028014528152 10.1148/radiol.2243011236 10.1016/j.ejps.2018.03.007 10.1001/jamaoncol.2018.3923 10.1158/2326-6066.CIR-15-0267 10.1002/mus.25141 10.1016/S2213-2600(18)30172-3 10.1089/cbr.2008.0607 10.1513/AnnalsATS.201603-179PS 10.1148/radiographics.20.5.g00se081245 10.1200/JCO.2016.68.2005 10.1183/13993003.02519-2017 10.1101/2020.07.15.20154609 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| DBID | 9YT ACMMV CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
| DOI | 10.1136/jitc-2020-001731 |
| DatabaseName | BMJ Journals (Open Access) BMJ Journals:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| ExternalDocumentID | oai_doaj_org_article_8744b96ba9a44fff9d9e0106c494995a 10_1136_jitc_2020_001731 33414264 ttps://jitc.bmj.com/content/9/1/e001731.full |
| Genre | Journal Article Comparative Study Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K08 HL132055 – fundername: NHLBI NIH HHS grantid: R01 HL151530 |
| GroupedDBID | -A0 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABDBF ABUWG ACGFS ACMMV ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU DIK FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PIMPY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP ACRMQ ADUKV AHSBF CGR CUY CVF EBS ECM EIF EJD H13 NPM ROL AAYXX CITATION 7XB 8FK AZQEC COVID DWQXO K9. PQEST PQUKI PRINS 5PM |
| ID | FETCH-LOGICAL-b526t-eb1ee9a5fe9f6497abf03f4142bc6a8a0619035c163ab63f9b768cdfb56da6303 |
| IEDL.DBID | RPM |
| ISSN | 2051-1426 |
| IngestDate | Tue Oct 22 15:12:05 EDT 2024 Tue Sep 17 21:10:54 EDT 2024 Thu Oct 10 15:08:35 EDT 2024 Thu Nov 21 23:21:57 EST 2024 Sat Nov 02 12:15:57 EDT 2024 Wed Aug 21 03:32:11 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | programmed cell death 1 receptor inflammation immunotherapy |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b526t-eb1ee9a5fe9f6497abf03f4142bc6a8a0619035c163ab63f9b768cdfb56da6303 |
| ORCID | 0000-0003-0275-8037 0000-0003-4163-2541 0000-0002-3470-8686 0000-0001-6697-3364 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797270/ |
| PMID | 33414264 |
| PQID | 2552986809 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8744b96ba9a44fff9d9e0106c494995a pubmedcentral_primary_oai_pubmedcentral_nih_gov_7797270 proquest_journals_2552986809 crossref_primary_10_1136_jitc_2020_001731 pubmed_primary_33414264 bmj_primary_10_1136_jitc_2020_001731 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Original research |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2021 |
| Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Naidoo, Wang, Woo 2017; 35 Petri, Patell, Batalini 2019; 27 Merrill, Reynolds, Kalra 2014; 48 Hallowell, Amariei, Danoff 2016; 13 Rashdan, Minna, Gerber 2018; 6 Akira, Ishikawa, Yamamoto 2002; 224 Andruska, Mahapatra, Hebbard 2018; 366 Boet, Katznelson, Castelluci 2020 Watson, Beardslee 2019 Melamed, Borte, Trawnicek 2018; 118 Nishino, Sholl, Hodi 2015; 373 Shiuan, Beckermann, Ozgun 2017; 5 Bhatraju, Ghassemieh, Nichols 2020; 382 Martins, Sykiotis, Maillard 2019; 20 Beattie, Fuentes, Rizvi 2020; 38 Wang, Salem, Cohen 2018; 4 Brahmer, Lacchetti, Schneider 2018; 36 Puzanov, Diab, Abdallah 2017; 5 Rossi, Erasmus, McAdams 2000; 20 Thompson, Schneider, Brahmer 2020; 18 Minor, Chin, Kashani-Sabet 2009; 24 Balaji, Verde, Suresh 2017; 31 Naidoo, Zhang, Lipson 2019; 17 Koyauchi, Inui, Karayama 2020; 2 Nishino, Chambers, Chong 2016; 4 Wiertz, van Moorsel, Van Moorsel 2018; 51 Kyi, Hellmann, Wolchok 2014; 2 Bledsoe, Nath, Decker 2017; 38 Kligerman, Franks, Galvin 2013; 33 Lau, Kumar, Yang 2016; 54 Johkoh, Itoh, Müller 1999; 211 38030305 - J Immunother Cancer. 2023 Nov 29;11(11) 33602697 - J Immunother Cancer. 2021 Feb;9(2) 36096536 - J Immunother Cancer. 2022 Sep;10(9) Balaji (2023112308150719000_9.1.e001731.7) 2017; 31 Naidoo (2023112308150719000_9.1.e001731.22) 2019; 17 2023112308150719000_9.1.e001731.30 Petri (2023112308150719000_9.1.e001731.11) 2019; 27 2023112308150719000_9.1.e001731.31 2023112308150719000_9.1.e001731.29 Wang (2023112308150719000_9.1.e001731.1) 2018; 4 Thompson (2023112308150719000_9.1.e001731.4) 2020; 18 2023112308150719000_9.1.e001731.24 2023112308150719000_9.1.e001731.25 2023112308150719000_9.1.e001731.26 Hallowell (2023112308150719000_9.1.e001731.19) 2016; 13 2023112308150719000_9.1.e001731.27 2023112308150719000_9.1.e001731.28 Lau (2023112308150719000_9.1.e001731.21) 2016; 54 2023112308150719000_9.1.e001731.20 2023112308150719000_9.1.e001731.18 Koyauchi (2023112308150719000_9.1.e001731.9) 2020; 2 Andruska (2023112308150719000_9.1.e001731.10) 2018; 366 Rashdan (2023112308150719000_9.1.e001731.5) 2018; 6 2023112308150719000_9.1.e001731.32 2023112308150719000_9.1.e001731.8 2023112308150719000_9.1.e001731.33 2023112308150719000_9.1.e001731.12 2023112308150719000_9.1.e001731.6 2023112308150719000_9.1.e001731.13 2023112308150719000_9.1.e001731.3 2023112308150719000_9.1.e001731.14 2023112308150719000_9.1.e001731.15 2023112308150719000_9.1.e001731.16 Bledsoe (2023112308150719000_9.1.e001731.23) 2017; 38 2023112308150719000_9.1.e001731.2 2023112308150719000_9.1.e001731.17 |
| References_xml | – volume: 366 year: 2018 article-title: Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy publication-title: BMJ Case Rep doi: 10.1136/bcr-2018-225937 contributor: fullname: Hebbard – volume: 5 start-page: 8 year: 2017 article-title: Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0210-0 contributor: fullname: Ozgun – volume: 31 year: 2017 article-title: Pneumonitis from Anti-PD-1/ PD-L1 therapy publication-title: Oncology contributor: fullname: Suresh – volume: 373 start-page: 288 year: 2015 article-title: Anti-PD-1–related pneumonitis during cancer immunotherapy publication-title: N Engl J Med doi: 10.1056/NEJMc1505197 contributor: fullname: Hodi – volume: 382 start-page: 2012 year: 2020 article-title: Covid-19 in Critically Ill Patients in the Seattle Region - Case Series publication-title: N Engl J Med doi: 10.1056/NEJMoa2004500 contributor: fullname: Nichols – year: 2020 article-title: Protocol for a multicentre randomized controlled trial of normobaric versus hyperbaric oxygen therapy for hypoxemic COVID-19 patients publication-title: medRxiv contributor: fullname: Castelluci – volume: 211 start-page: 155 year: 1999 article-title: Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings publication-title: Radiology doi: 10.1148/radiology.211.1.r99ap10155 contributor: fullname: Müller – volume: 2 start-page: 570 year: 2020 article-title: Clinical outcomes of Anti-programmed death-1 Antibody–Related pneumonitis in patients with non-small cell lung cancer publication-title: SN Compr Clin Med doi: 10.1007/s42399-020-00259-3 contributor: fullname: Karayama – volume: 36 start-page: 1714 year: 2018 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.6385 contributor: fullname: Schneider – volume: 2 start-page: 19 year: 2014 article-title: Opportunistic infections in patients treated with immunotherapy for cancer publication-title: J Immunother Cancer doi: 10.1186/2051-1426-2-19 contributor: fullname: Wolchok – volume: 38 year: 2020 article-title: Success and failure of additional immunosuppressants in steroid-refractory pneumonitis related to immune checkpoint blockade publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.3078 contributor: fullname: Rizvi – volume: 18 start-page: 230 year: 2020 article-title: NCCN guidelines insights: management of Immunotherapy-Related toxicities, version 1.2020 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2020.0012 contributor: fullname: Brahmer – volume: 20 start-page: e54 year: 2019 article-title: New therapeutic perspectives to manage refractory immune checkpoint-related toxicities publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30828-3 contributor: fullname: Maillard – volume: 5 start-page: 95 year: 2017 article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0300-z contributor: fullname: Abdallah – volume: 33 start-page: 1951 year: 2013 article-title: From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia publication-title: Radiographics doi: 10.1148/rg.337130057 contributor: fullname: Galvin – volume: 17 start-page: 712 year: 2019 article-title: A multidisciplinary toxicity team for cancer Immunotherapy-Related adverse events publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.7268 contributor: fullname: Lipson – volume: 27 start-page: 100834 year: 2019 article-title: Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature publication-title: Respir Med Case Rep doi: 10.1016/j.rmcr.2019.100834 contributor: fullname: Batalini – volume: 38 start-page: 201 year: 2017 article-title: Radiation pneumonitis publication-title: Clin Chest Med doi: 10.1016/j.ccm.2016.12.004 contributor: fullname: Decker – volume: 48 start-page: 806 year: 2014 article-title: Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient publication-title: Ann Pharmacother doi: 10.1177/1060028014528152 contributor: fullname: Kalra – volume: 224 start-page: 852 year: 2002 article-title: Drug-induced pneumonitis: thin-section CT findings in 60 patients publication-title: Radiology doi: 10.1148/radiol.2243011236 contributor: fullname: Yamamoto – volume: 118 start-page: 80 year: 2018 article-title: Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2018.03.007 contributor: fullname: Trawnicek – volume: 51 year: 2018 article-title: Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease publication-title: Eur Respiratory Soc contributor: fullname: Van Moorsel – volume: 4 start-page: 1721 year: 2018 article-title: Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.3923 contributor: fullname: Cohen – volume: 4 start-page: 289 year: 2016 article-title: Anti–PD-1 inhibitor–related pneumonitis in non-small cell lung cancer publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0267 contributor: fullname: Chong – year: 2019 article-title: Management of steroid-refractory immune-related adverse events publication-title: Oncology contributor: fullname: Beardslee – volume: 54 start-page: 157 year: 2016 article-title: Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab publication-title: Muscle Nerve doi: 10.1002/mus.25141 contributor: fullname: Yang – volume: 6 start-page: 472 year: 2018 article-title: Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30172-3 contributor: fullname: Gerber – volume: 24 start-page: 321 year: 2009 article-title: Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis publication-title: Cancer Biother Radiopharm doi: 10.1089/cbr.2008.0607 contributor: fullname: Kashani-Sabet – volume: 13 start-page: 1682 year: 2016 article-title: Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201603-179PS contributor: fullname: Danoff – volume: 20 start-page: 1245 year: 2000 article-title: Pulmonary drug toxicity: radiologic and pathologic manifestations publication-title: Radiographics doi: 10.1148/radiographics.20.5.g00se081245 contributor: fullname: McAdams – volume: 35 start-page: 709 year: 2017 article-title: Pneumonitis in patients treated with Anti-Programmed Death-1/Programmed death ligand 1 therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.2005 contributor: fullname: Woo – volume: 366 year: 2018 ident: 2023112308150719000_9.1.e001731.10 article-title: Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy publication-title: BMJ Case Rep contributor: fullname: Andruska – volume: 2 start-page: 570 year: 2020 ident: 2023112308150719000_9.1.e001731.9 article-title: Clinical outcomes of Anti-programmed death-1 Antibody–Related pneumonitis in patients with non-small cell lung cancer publication-title: SN Compr Clin Med doi: 10.1007/s42399-020-00259-3 contributor: fullname: Koyauchi – ident: 2023112308150719000_9.1.e001731.27 doi: 10.1148/rg.337130057 – ident: 2023112308150719000_9.1.e001731.14 doi: 10.1186/2051-1426-2-19 – ident: 2023112308150719000_9.1.e001731.8 doi: 10.1016/S1470-2045(18)30828-3 – volume: 54 start-page: 157 year: 2016 ident: 2023112308150719000_9.1.e001731.21 article-title: Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab publication-title: Muscle Nerve doi: 10.1002/mus.25141 contributor: fullname: Lau – ident: 2023112308150719000_9.1.e001731.6 – ident: 2023112308150719000_9.1.e001731.24 doi: 10.1148/radiol.2243011236 – volume: 13 start-page: 1682 year: 2016 ident: 2023112308150719000_9.1.e001731.19 article-title: Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease publication-title: Ann Am Thorac Soc contributor: fullname: Hallowell – volume: 17 start-page: 712 year: 2019 ident: 2023112308150719000_9.1.e001731.22 article-title: A multidisciplinary toxicity team for cancer Immunotherapy-Related adverse events publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.7268 contributor: fullname: Naidoo – ident: 2023112308150719000_9.1.e001731.12 doi: 10.1200/JCO.2020.38.15_suppl.3078 – ident: 2023112308150719000_9.1.e001731.17 doi: 10.1177/1060028014528152 – ident: 2023112308150719000_9.1.e001731.2 doi: 10.1200/JCO.2016.68.2005 – ident: 2023112308150719000_9.1.e001731.28 doi: 10.1056/NEJMoa2004500 – ident: 2023112308150719000_9.1.e001731.29 – volume: 4 start-page: 1721 year: 2018 ident: 2023112308150719000_9.1.e001731.1 article-title: Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.3923 contributor: fullname: Wang – volume: 27 start-page: 100834 year: 2019 ident: 2023112308150719000_9.1.e001731.11 article-title: Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature publication-title: Respir Med Case Rep contributor: fullname: Petri – volume: 18 start-page: 230 year: 2020 ident: 2023112308150719000_9.1.e001731.4 article-title: NCCN guidelines insights: management of Immunotherapy-Related toxicities, version 1.2020 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2020.0012 contributor: fullname: Thompson – volume: 6 start-page: 472 year: 2018 ident: 2023112308150719000_9.1.e001731.5 article-title: Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30172-3 contributor: fullname: Rashdan – ident: 2023112308150719000_9.1.e001731.13 doi: 10.1056/NEJMc1505197 – ident: 2023112308150719000_9.1.e001731.26 doi: 10.1148/radiographics.20.5.g00se081245 – ident: 2023112308150719000_9.1.e001731.20 doi: 10.1186/s40425-017-0210-0 – ident: 2023112308150719000_9.1.e001731.16 doi: 10.1200/JCO.2017.77.6385 – ident: 2023112308150719000_9.1.e001731.32 doi: 10.1183/13993003.02519-2017 – volume: 31 year: 2017 ident: 2023112308150719000_9.1.e001731.7 article-title: Pneumonitis from Anti-PD-1/ PD-L1 therapy publication-title: Oncology contributor: fullname: Balaji – ident: 2023112308150719000_9.1.e001731.15 doi: 10.1186/s40425-017-0300-z – ident: 2023112308150719000_9.1.e001731.18 doi: 10.1089/cbr.2008.0607 – volume: 38 start-page: 201 year: 2017 ident: 2023112308150719000_9.1.e001731.23 article-title: Radiation pneumonitis publication-title: Clin Chest Med doi: 10.1016/j.ccm.2016.12.004 contributor: fullname: Bledsoe – ident: 2023112308150719000_9.1.e001731.33 doi: 10.1101/2020.07.15.20154609 – ident: 2023112308150719000_9.1.e001731.3 doi: 10.1158/2326-6066.CIR-15-0267 – ident: 2023112308150719000_9.1.e001731.25 doi: 10.1148/radiology.211.1.r99ap10155 – ident: 2023112308150719000_9.1.e001731.30 doi: 10.1016/j.ejps.2018.03.007 – ident: 2023112308150719000_9.1.e001731.31 |
| SSID | ssj0001033888 |
| Score | 2.4209237 |
| Snippet | BackgroundImmune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is... Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed... Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is... |
| SourceID | doaj pubmedcentral proquest crossref pubmed bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | e001731 |
| SubjectTerms | Adrenal Cortex Hormones - therapeutic use Adult Aged Aged, 80 and over Cancer Cell death Chemotherapy Clinical/Translational Cancer Immunotherapy Drug Resistance - drug effects Fatalities Female Hospitalization Humans Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunoglobulins Immunoglobulins, Intravenous - administration & dosage Immunoglobulins, Intravenous - therapeutic use Immunotherapy Incidence Infliximab - administration & dosage Intensive Care Units Laboratories Lung Neoplasms - drug therapy Lung Neoplasms - epidemiology Male Middle Aged Multidisciplinary teams Outpatient care facilities Patients Pneumonia - drug therapy Pneumonia - epidemiology Radiation Retrospective Studies Survival Analysis Ventilators |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB3BHiouVT-gDdDKBw5F2ggncfzRW1tYcYAKiVbigizbsdVFIovI7qH_nrGTXbEIqT1wTazYejOO39jjNwAHVBnlkWfgRKplzlhd5arkLjeUusJYby2Pt5FPL8XPK3l8EmVyVqW-Yk5YLw_cA3cU5dmt4tYow1gIQTXKxzjGJVmVuqdGVDwKptLuCsXQS8rluWTFj26mc4cuUcZ71IWINeU27e3N2mqURPufY5pPEyYfrUCTN_B6oI7kWz_kt7Dh23fw6nw4HH8P15eI0Wza5NjNfSqj85dcHOdfzg4Lctf6xW2cvtPuK4nb66mU6JgsL0aS4JPCZzcmq9TzMTFtQ2aLOTql77bh9-Tk14_TfKiekNu65PMcf8LeKxOTyQJnShgbaBVYwUrruJEGF3JFq9ohITOWV0FZjDxcE2zNG8NxZduBUTtr_UcgpRJBGF4UBumVlMw21jLuaIGfc8inMjhALPVdr4-hU1xRcR0h1xFy3UOeweES7P9o-z1aY9UuqmCnB-gbevAN_S_fyGB_aUs9TM1OYwxVKsklVRl86M266qWqIj6cZSDWDL42jPU37fRPEuUWQiEVpLsvMe492Cpj6kza6dmH0fx-4T_BZtcsPic3fwAsR_9q priority: 102 providerName: Directory of Open Access Journals |
| Title | Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes |
| URI | http://dx.doi.org/10.1136/jitc-2020-001731 https://www.ncbi.nlm.nih.gov/pubmed/33414264 https://www.proquest.com/docview/2552986809 https://pubmed.ncbi.nlm.nih.gov/PMC7797270 https://doaj.org/article/8744b96ba9a44fff9d9e0106c494995a |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB41PVRcUKE8lraRDz1QKdt4X16bW-lDraBVpRaJC7Jsrw1bkU2UTQ78e8bObtQgDojrvuydGXu-Gc8D4IgKJSziDFxIBY_zvMhikTITK0pNorTVmvls5Kv78vYrP7_wZXKKPhcmBO0bXZ80PycnTf0jxFbOJmbcx4mN727OylKg2qXjAQwQGz4x0YNjhaLVxXl_JJmx8WO9MCgNqU-hTsrMN4fJcPP2WAA1ip48buikULr_b3jzz7DJJ3rocheedwCSnK4m-gK2bPMSdm66I_I9-HaPlJrWVYzDzEMznV_k7jx-__k4IbPGLid-EdftB-Kd7KGh6Ij06ZHE2VDnsx2RdQD6iKimItPlAkXTtq_gy-XFw9lV3PVQiHWRskWMW7G1QvmQMsdyUSrtaOb8z2vDFFeozgXNCoOwTGmWOaHR_jCV0wWrFEP99hq2m2lj3wJJRelKxZJEIcjiPNeV1jkzNMHPGURVERwhLeVsVSVDBusiY9JTX3rqyxX1Izjuif0Pz3703Fg_52thhwvT-XfZSYT0Bfy1YFoJlefOOVEJ6y1dEwrvFCqCg56XslugrURLKhWccSoieLNi63qUXjgiKDcYvjGNzTsoqaE0dyeZ7_77zX14lvqomeDkOYDtxXxpD2HQVsshAv7rT8PgNBgGkf8NuBQB_Q |
| link.rule.ids | 230,315,729,782,786,866,887,2107,27934,27935,53802,53804 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB7RIgEX3oWFAj70QKVs4315bW7Qh4JIqkotEhdk2V4btiKbKJsc-PeMnd2oQRxQr2vvyzPj-cae-QxwQIUSFnEGGlLB4zwvslikzMSKUpMobbVmvhp5dFmef-Mnp54mp-hrYULSvtH1UfNretTUP0Nu5Xxqhn2e2PBiclyWAt0uHe7AXbRXmt4I0sPSCsW4i_N-UzJjw-t6aVAfUl9EnZSZPx4mw-nbowH0KXp6veWVAnn_vxDn34mTNzzR2aNb_sNjeNhBT_Jx3fwE7tjmKdybdJvrz-D7JY7xrK5i_LxFOIbnN7k4id-PDxMyb-xq6s2_bj8QvzwfjiIdkL6wkjgbGELbAdmkrg-IaioyWy1RqW37HL6enV4dj-Lu9IVYFylbxjiJWyuUT0ZzLBel0o5mzg-aNkxxhUBA0KwwCOiUZpkTGiMXUzldsEox9Ix7sNvMGvsSSCpKVyqWJArhGee5rrTOmaEJPs4gHovgAGUg52t-DRnikoxJLzXppSbXUovgsBfSf_T95KW46edZtMOF2eKH7OQgPfW_FkwrofLcOScqYX2MbAJlT6Ei2O91QHam3UqMwVLBGacighdrddi8pVeqCMotRdn6jO0W1I9A6t3pw6tb3_kO7o-uJmM5_nz-5TU8SH3uTVgq2ofd5WJl38BOW63eBlP5A7fYFaA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlVcyhsCLfjQA5U2jfNyYm6021URbbVSQeKCLNuxIVU3u9rsHvrvO_Ymqy7igOCaOInj-cbzjT2eATigXHKDPAMVKS_DLMvTkCdMh5JSHUtllGLuNPLZVXH5vRyeujQ561JfPmhfq_qouZkcNfUvH1s5m-iojxOLxhcnRcHR7NJoVtloCx6iztLsnqPul1co-l5l2W9Mpiy6rhcaMZG4g9RxkboSMSlO4Y4RoF1Rk-sNy-QT-P-Jdf4ePHnPGo0e_8d_PIHdjoKST6smT-GBaZ7BzkW3yf4cflzhWE_rKsQuzn05nlsyHoYfzg9jMmvMcuKmgbr9SNwyvS9JOiD9AUtijc8U2g7IOoR9QGRTkelygeA27Qv4Njr9enIWdlUYQpUnbBHiZG4Mly4ozbKMF1JZmlo3cEozWUokBJymuUZiJxVLLVfowejKqpxVkqGFfAnbzbQxr4EkvLCFZHEskaaVZaYqpTKmaYyv08jLAjhAOYjZKs-G8P5JyoSTnHCSEyvJBXDYC-ov2h47Sa7buWza_sJ0_lN0shCuBIDiTEkus8xayytunK-sfeqeXAaw1-NAdCreCvTFEl6ykvIAXq0gsf5KD6wAig2wbHRj8w5ixCf37jDx5p-ffA874-FInH--_PIWHiUuBMevGO3B9mK-NPuw1VbLd15b7gCDShgg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Steroid-refractory+PD-%28L%291+pneumonitis%3A+incidence%2C+clinical+features%2C+treatment%2C+and+outcomes&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Aanika+Balaji&rft.au=Hsu%2C+Melinda&rft.au=Lin%2C+Cheng+Ting&rft.au=Feliciano%2C+Josephine&rft.date=2021-01-01&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=2051-1426&rft.volume=9&rft.issue=1&rft.spage=e001731&rft_id=info:doi/10.1136%2Fjitc-2020-001731&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |